Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Minority Interest (2021 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Minority Interest for 5 consecutive years, with -$952000.0 as the latest value for Q3 2025.

  • Quarterly Minority Interest fell 3.59% to -$952000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$952000.0 through Sep 2025, down 3.59% year-over-year, with the annual reading at -$918000.0 for FY2024, 1.08% up from the prior year.
  • Minority Interest hit -$952000.0 in Q3 2025 for Oramed Pharmaceuticals, down from -$946000.0 in the prior quarter.
  • Over the last five years, Minority Interest for ORMP hit a ceiling of $1.1 million in Q2 2021 and a floor of -$952000.0 in Q3 2025.
  • Median Minority Interest over the past 5 years was -$896500.0 (2023), compared with a mean of -$542833.3.
  • Biggest five-year swings in Minority Interest: crashed 552.38% in 2023 and later rose 1.08% in 2024.
  • Year by year, Minority Interest stood at $536000.0 in 2021, then crashed by 222.39% to -$656000.0 in 2022, then tumbled by 41.46% to -$928000.0 in 2023, then grew by 1.08% to -$918000.0 in 2024, then fell by 3.7% to -$952000.0 in 2025.
  • Business Quant data shows Minority Interest for ORMP at -$952000.0 in Q3 2025, -$946000.0 in Q2 2025, and -$918000.0 in Q1 2025.